Genmab ADR (NASDAQ: GMAB) has a price-to-earnings ratio of 11.53x that is above its average ratio. Additionally, the 36-month beta value for GMAB is 0.95. There are mixed opinions on the stock, with 4 analysts rating it as a “buy”, 1 rating it as “overweight”, 4 rating it as “hold”, and 0 rating it as “sell”.
The public float for GMAB is 615.07M and currently, short sellers hold a 0.36% ratio of that float. The average trading volume of GMAB on July 03, 2025 was 1.53M shares.
GMAB stock’s latest price update
Genmab ADR (NASDAQ: GMAB)’s stock price has dropped by -0.51% in relation to previous closing price of $20.44. Nevertheless, the company has seen a loss of -1.91% in its stock price over the last five trading days. globenewswire.com reported 2025-07-01 that Media Release COPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/S Greg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 Genmab A/S (Nasdaq: GMAB ) a nnounced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will retire from Genmab after a successful tenure that spanned 23 years with the company. Greg Mueller joins Genmab A/S as Executive Vice President, General Counsel and Chief Legal Officer effective July 1.
GMAB’s Market Performance
Genmab ADR (GMAB) has experienced a -1.91% fall in stock performance for the past week, with a -4.75% drop in the past month, and a 8.05% rise in the past quarter. The volatility ratio for the week is 1.69%, and the volatility levels for the past 30 days are at 1.75% for GMAB. The simple moving average for the past 20 days is -5.55% for GMAB’s stock, with a -4.87% simple moving average for the past 200 days.
GMAB Trading at -3.03% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.80% of loss for the given period.
Volatility was left at 1.75%, however, over the last 30 days, the volatility rate increased by 1.69%, as shares sank -6.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.30% upper at present.
During the last 5 trading sessions, GMAB fell by -1.93%, which changed the moving average for the period of 200-days by -24.42% in comparison to the 20-day moving average, which settled at $21.53. In addition, Genmab ADR saw -18.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Genmab ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.34% for the present operating margin
- 0.95% for the gross margin
The net margin for Genmab ADR stands at 0.37%. The total capital return value is set at 1.04%. Equity return is now at value 22.69%, with 19.07% for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 45.77. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 63.44.
Currently, EBITDA for the company is 9.7 billion with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 4.31. The receivables turnover for the company is 22.65for trailing twelve months and the total asset turnover is 2.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.34.
Conclusion
In conclusion, Genmab ADR (GMAB) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
